CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 565 enrolled
Drug / intervention
BBI608 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01325441
NCT01325441Phase 2Completed
CompareCT.gov

A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Sumitomo Pharma America, Inc.·interventional·Posted Mar 29, 2011·Updated Nov 15, 2023

In Brief

A Phase 2 clinical trial evaluating BBI608 and Paclitaxel for Cancer. Completed, enrolled 565 participants across 22 sites in 2 countries.

Detailed Summary

This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 29, 2011
Enrollment StartApr 1, 2011
Primary CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 10.2 yearsPosted 15.3 years ago

Interventions

BBI608drug

Paclitaxeldrug